Abstract
The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Current Molecular Medicine
Title: Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor
Volume: 2 Issue: 8
Author(s): B. K. Patterson, A. Tjernlund and J. Andersson
Affiliation:
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Abstract: The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Export Options
About this article
Cite this article as:
Patterson K. B., Tjernlund A. and Andersson J., Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor, Current Molecular Medicine 2002; 2 (8) . https://dx.doi.org/10.2174/1566524023361817
DOI https://dx.doi.org/10.2174/1566524023361817 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows
Current Drug Targets Immunotherapy for Food Allergy
Inflammation & Allergy - Drug Targets (Discontinued) A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Appraisal of Saxagliptin as Treatment of Type 2 Diabetes
Current Drug Therapy Effect of Variable Doses of Paederia foetida L. Combat Against Experimentally- Induced Systemic and Topical Inflammation in Wistar Rats
Current Bioactive Compounds Redox Regulation of Fertility in Aging Male and the Role of Antioxidants: A Savior or Stressor
Current Pharmaceutical Design Patent Selections
Recent Patents on Engineering Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics Editorial [Hot topic: Updates on Therapeutic Approaches to Inflammatory Skin Diseases: From Molecular Targets to Drug Development. Part II (Guest Editors: L. Korkina & S. Pastore)]
Current Drug Metabolism Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis
Current Drug Delivery Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design Novel, Acidic CCR2 Receptor Antagonists: From Hit to Lead
Letters in Drug Design & Discovery SUBJECT INDEX TO VOLUME 1
Current Drug Targets The Role of Intravascular Ultrasound to Guide Drug-Eluting Stents Implantation
Cardiovascular & Hematological Agents in Medicinal Chemistry Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) Membrane Permeabilization by Multivalent Anti-Microbial Peptides
Protein & Peptide Letters